Topic: Policy: Value Assessment and International Reference Pricing

Special Assessment to Inform CMS Drug Price Negotiation: Breo Ellipta and Trelegy Ellipta

Mar 2025 | Policy Paper

Interventions of interest: ICER will develop a special report for CMS on two therapies in high demand for treating chronic obstructive pulmonary disease (COPD). This report will be submitted to CMS as part of the 2025 public comment process defined in CMS guidance on Medicare Drug Price Negotiations for price applicability year 2027.  Date of publication: March […]

Special Assessment to Inform CMS Drug Price Negotiation: Eliquis and Xarelto

Oct 2023 | Policy Paper

ICER developed a special report evaluating the evidence on apixaban (Eliquis®, Bristol Myers Squibb) and rivaroxaban (Xarelto®, Bayer) for the treatment of nonvalvular atrial fibrillation (NVAF). ICER submitted this report to the Centers for Medicare and Medicaid Services (CMS) as part of the public comment process defined in CMS guidance.  The report was tailored to […]

Value Assessment and International Reference Pricing

Sep 2021 | Policy Paper

The need to improve drug affordability remains one of the few areas of bipartisan agreementin the US, with polling showing that a majority of both Democrats and Republicans want thefederal government to act to lower prescription drug prices. Policymakers from both partieshave advanced proposals to rein in drug costs, but there is no consensus on […]